We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Rtw Biotech Opportunities Ltd | LSE:RTW | London | Ordinary Share | GG00BKTRRM22 | ORD NPV |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.01 | -0.66% | 1.51 | 6,000 | 08:00:26 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1.51 | 1.57 | 1.51 | 1.51 | 1.51 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Trust,ex Ed,religious,charty | 4.17M | -4.76M | -0.0123 | -123.58 | 587M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 08:12:46 | AT | 5,992 | 1.51 | USD |
| Date | Time | Source | Headline |
|---|---|---|---|
| 03/10/2024 | 12:59 | ALNC |  RTW Biotech Opportunities announces launch of Kailera Therapeutics |
| 03/10/2024 | 07:00 | UK RNS | RTW Biotech Opportunities Ltd Launch of Obesity Company Kailera.. |
| 02/10/2024 | 11:05 | ALNC | IN BRIEF: RTW Biotech invests in cancer treatment firm Aktis Oncology |
| 02/10/2024 | 07:00 | UK RNS | RTW Biotech Opportunities Ltd New Investment in Aktis Oncology |
| 27/9/2024 | 12:19 | ALNC | RTW Biotech notes BioAge Labs' USD198 million initial public offering |
| 27/9/2024 | 07:00 | UK RNS | RTW Biotech Opportunities Ltd BioAge Labs completes $198 million IPO |
| 26/9/2024 | 07:00 | UK RNS | RTW Biotech Opportunities Ltd GBP quote for the share class to cease |
| 16/9/2024 | 07:00 | UK RNS | RTW Biotech Opportunities Ltd Monthly Valuation Update and Factsheet |
| 13/9/2024 | 10:48 | ALNC | RTW Biotech half-year net asset value rises amid "challenging markets" |
| 13/9/2024 | 07:00 | UK RNS | RTW Biotech Opportunities Ltd Half-year Report |
Rtw Biotech Opportunities (RTW) Share Charts1 Year Rtw Biotech Opportunities Chart |
|
1 Month Rtw Biotech Opportunities Chart |
Intraday Rtw Biotech Opportunities Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 03/10/2024 | 16:53 | ::: RTW VENTURE FUND ::: | 45 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 07:12:46 | 1.51 | 5,992 | 0.00 | AT |
| 07:00:26 | 1.51 | 8 | 0.00 | UT |
| Top Posts |
|---|
Posted at 07/10/2024 09:20 by Rtw Biotech Opportunities Daily Update Rtw Biotech Opportunities Ltd is listed in the Trust,ex Ed,religious,charty sector of the London Stock Exchange with ticker RTW. The last closing price for Rtw Biotech Opportunities was US$1.52.Rtw Biotech Opportunities currently has 386,186,512 shares in issue. The market capitalisation of Rtw Biotech Opportunities is £587,003,498. Rtw Biotech Opportunities has a price to earnings ratio (PE ratio) of -123.58. This morning RTW shares opened at US$1.51 |
Posted at 03/10/2024 16:53 by rambutan2 But smid US biotech remains becalmed for the time being: |
Posted at 03/10/2024 16:40 by rambutan2 Also had an IPO and another new investment over the last couple of weeks: |
Posted at 03/10/2024 16:38 by rambutan2 Their play on a huge, albeit currently very competitive, mkt:Roderick Wong, Managing Partner and CIO at the Investment Manager commented on the launch, "We are immensely proud to co-lead the Series A launch of Kailera Therapeutics, our fourth new company creation at RTW. Kailera represents a significant step forward in addressing the huge market for chronic weight management and metabolic diseases. With its clinically-validated pipeline and experienced management team, we are confident that Kailera is well-positioned to develop breakthrough therapies that will profoundly improve the lives of patients worldwide. We look forward to supporting them on this transformative journey." |
Posted at 15/9/2024 23:00 by rambutan2 Interim report, released on fri, is a good read, with some interesting portfolio details: |
Posted at 16/7/2024 20:45 by rambutan2 End of quarter update etc. Still on sale on a 20% discount and in a still beaten down sector... |
Posted at 11/6/2024 12:06 by affemoose Investment Subsid' sale - $4.5m for RTWhxxps://www.marketsc |
Posted at 23/3/2024 20:39 by rambutan2 Apogee (APGE) is another big, up 50%, riser this month on the back of trial news and subsequent raise. RTW was a backer from pre IPO at multiples lower. |
Posted at 21/3/2024 22:09 by rambutan2 Yes, very wrongly priced currently. The sector trades on around a 10% discount, so this has got really out of wack. And especially so considering it is a top performer and has a quality manager. It offers a rare opportunity to buy a real no brainer. imho.Sector stats: I note that in the last fact sheet, Avidity came from nowhere to be 9% of nav. Since then, it is up approx 40% on good news and a fund raise in which RTW participated. This just illustrates one of the great advantages offered by being part of the RTW platform, one of the elite bio investors in the States. |
Posted at 21/2/2024 15:10 by jaf111 Agree that it certainly looks attractive but have to admit being very disappointed with the $1.88 proforma number.When the “merger” was announced last November RTW stated it was expected to be immediately accretive to RTW NAV per share…… But the end Jan (pre merger) NAV was $1.94 per share……. Have I missed something?????? |
Posted at 13/2/2024 09:26 by hpcg There will be some momentary pressure to the share price from former ARIX holders in for the trade, but buy back program should mitigate that. In the meantime biotech seems to have bottomed and there are exciting new opportunities with those using AI to sift molecules. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
